These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28314412)

  • 61. Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.
    Cogo S; Greggio E; Lewis PA
    Expert Opin Ther Targets; 2017 Aug; 21(8):751-753. PubMed ID: 28609155
    [No Abstract]   [Full Text] [Related]  

  • 62. Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.
    Osborne J; Birchall K; Tsagris DJ; Lewis SJ; Smiljanic-Hurley E; Taylor DL; Levy A; Alessi DR; McIver EG
    Bioorg Med Chem Lett; 2019 Feb; 29(4):668-673. PubMed ID: 30554956
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization.
    De Wit T; Baekelandt V; Lobbestael E
    Mol Neurobiol; 2019 Aug; 56(8):5273-5286. PubMed ID: 30592011
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Concurrent Optimizations of Efficacy and Blood-Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson's Disease Therapeutics.
    Kim K; Jang A; Shin H; Ye I; Lee JE; Kim T; Park H; Hong S
    J Med Chem; 2024 May; 67(9):7647-7662. PubMed ID: 38684226
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.
    Thirstrup K; Dächsel JC; Oppermann FS; Williamson DS; Smith GP; Fog K; Christensen KV
    Sci Rep; 2017 Aug; 7(1):10300. PubMed ID: 28860483
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and biological evaluation of[
    Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P
    Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2.
    Liou GY; Gallo KA
    Biochem J; 2009 Oct; 424(1):e1-3. PubMed ID: 19839940
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease.
    Rautio J
    J Med Chem; 2012 Nov; 55(22):9414-5. PubMed ID: 23078245
    [No Abstract]   [Full Text] [Related]  

  • 72. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity.
    Bryce DK; Ware CM; Woodhouse JD; Ciaccio PJ; Ellis JM; Hegde LG; Kuruvilla S; Maddess ML; Markgraf CG; Otte KM; Poulet FM; Timmins LM; Kennedy ME; Fell MJ
    J Pharmacol Exp Ther; 2021 Apr; 377(1):11-19. PubMed ID: 33509901
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular Insights and Functional Implication of LRRK2 Dimerization.
    Civiero L; Russo I; Bubacco L; Greggio E
    Adv Neurobiol; 2017; 14():107-121. PubMed ID: 28353281
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.
    Ding X; Stasi LP; Dai X; Long K; Peng C; Zhao B; Wang H; Sun C; Hu H; Wan Z; Jandu KS; Philps OJ; Chen Y; Wang L; Liu Q; Edge C; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
    Bioorg Med Chem Lett; 2019 Jan; 29(2):212-215. PubMed ID: 30522952
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
    Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW
    PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors.
    Smith GP; Badolo L; Chell V; Chen IJ; Christensen KV; David L; Daechsel JA; Hentzer M; Herzig MC; Mikkelsen GK; Watson SP; Williamson DS
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4500-4505. PubMed ID: 28802631
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
    Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
    Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.